iqvia semaglutide tirzepatide prescriptions us q3 2024 Novo said its research shows Medicare recipients are twice as likely to prefer a weight-loss pill to a shot, a preference it hopes will help it win market share from rival US FDA warns online vendors

This helps your body readjust to the medication while minimizing side effects

The effect of spironolactone on morbidity and mortality in patients with severe heart failure

Colatrella A, Loguercio V, Mattei L, Trappolini M, Festa C, Stoppo M, Napoli A

The food noise may not be as loud as it was, but the subtle hunger cues are still there

El dato que el marketing suele callar lo da SURMOUNT-4 , un ensayo de retirada: tras 36 semanas de tratamiento con una prdida media del 20,9%, quien dej el frmaco recuper peso mientras quien lo mantuvo sigui perdiendo (otro 5,5%, hasta un 26% total)

The latter estimates a rate of decline over three generations of -71% (-91%, -12%) (Figure 3)